HZ-S109
/ HealZen Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
HZ-S109, a potent and selective HPK1 degrader with enhanced T cell modulation efficacy and improved bioavailability
(AACR 2025)
- "HZ-S109 exhibits potent HPK1 degradation with DC50 values lower than 10 nM across various cell types, including Jurkat, Ramos, PBMC, and CAR-T cells. Importantly, HZ-S109 demonstrated no significant effect on other family members, such as GCK, GLK, HGK, or KHS. HZ-S109 can significantly enhance the activation of primary T cell at nanomolar level concentrations, with the maximum activation fold exceeding 15-fold."
Clinical • Oncology • LCP2 • TGFB1
1 to 1
Of
1
Go to page
1